Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib
We used 2-deoxy-2-[18F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate patients with desmoid tumors undergoing therapy with imatinib. The study included 22 patients with progressive disease (PD) of a biopsy proven desmoid tumor treated orally with imatinib 800 mg daily. Patien...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2013-01, Vol.2013 (2013), p.1-7 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | 2013 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2013 |
| creator | Sachpekidis, Christos Strauss, Ludwig G. Pilz, Lothar R. Dimitrakopoulou-Strauss, Antonia Kasper, Bernd Hohenberger, Peter |
| description | We used 2-deoxy-2-[18F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate patients with desmoid tumors undergoing therapy with imatinib. The study included 22 patients with progressive disease (PD) of a biopsy proven desmoid tumor treated orally with imatinib 800 mg daily. Patients were examined using PET prior to onset of therapy and during treatment. Restaging was performed in parallel using computed tomography (CT) and/or magnetic resonance imaging (MRI). Outcome of 22 evaluable patients was as follows: five patients with partial response (PR); twelve patients with stable disease (SD) accounting for 77% with non-progressive disease; five patients showed PD. A 30% decrease of the mean average standardized uptake value (SUV) of sequential PET examinations could be demonstrated; no patient demonstrated a substantial increase in SUV. Patients with PR/SD were matched to a group of nonprogressive disease and tested versus PD. The initial average SUV and SUVmax seem to be candidates for a response prediction with an approximate P-value of 0.06553 and 0.07785, respectively. This is the first larger series of desmoid patients monitored using PET showing that early SUV changes may help to discriminate responders from nonresponders and, thus, to decide whether imatinib therapy should be continued. |
| doi_str_mv | 10.1155/2013/389672 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3671300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A373372700</galeid><sourcerecordid>A373372700</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-e7cad89d9727cbe13fb4867542e8d676a5850d3babd6e6114bb93b5bbd335c7c3</originalsourceid><addsrcrecordid>eNqNks1u1DAUhSMEolXpij2yxAaBhvovtrNBqsoAlYqoIKwtO7mZcUnsqZ20mufghfGQMhQ24I2vfD8fXx-donhK8GtCyvKEYsJOmKqEpA-KQ8oIXwjCycN9zdhBcZzSFc5LEYEr8bg4oEwKqjg9LL5fhuTGGDxaDi4ll4s6DGEVzWa9RSYhg75MMYaVGQF9NPEbRNSFiJY3pp_MuONDh-oIZhzAj-gzpE3wCZDz6DL381lCt25co7eQhuBaVE9DiAlNvs1S9RryS9uZOB_yBe_sk-JRZ_oEx3f7UfH13bI--7C4-PT-_Oz0YtGUVI0LkI1pVdVWksrGAmGd5UrIklNQrZDClKrELbPGtgIEIdzaitnS2paxspENOyrezLqbyQ7QNnnWaHq9iW4wcauDcfrPjndrvQo3mglJGMZZ4MWdQAzXE6RRZw8b6HvjIUxJE84VpbSU5b_RrKmkpFxl9Plf6FWYos9OZEGqMJayqn5TK9ODdr4LecRmJ6pPmWQsm_Jzwlcz1cSQUoRu_zuC9S5AehcgPQco08_uG7Jnf8UlAy9nYO18a27d_6lBRqAz92CGeSXYD-j22G4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1428007799</pqid></control><display><type>article</type><title>Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Sachpekidis, Christos ; Strauss, Ludwig G. ; Pilz, Lothar R. ; Dimitrakopoulou-Strauss, Antonia ; Kasper, Bernd ; Hohenberger, Peter</creator><contributor>Nikolic, Aleksandra</contributor><creatorcontrib>Sachpekidis, Christos ; Strauss, Ludwig G. ; Pilz, Lothar R. ; Dimitrakopoulou-Strauss, Antonia ; Kasper, Bernd ; Hohenberger, Peter ; Nikolic, Aleksandra</creatorcontrib><description>We used 2-deoxy-2-[18F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate patients with desmoid tumors undergoing therapy with imatinib. The study included 22 patients with progressive disease (PD) of a biopsy proven desmoid tumor treated orally with imatinib 800 mg daily. Patients were examined using PET prior to onset of therapy and during treatment. Restaging was performed in parallel using computed tomography (CT) and/or magnetic resonance imaging (MRI). Outcome of 22 evaluable patients was as follows: five patients with partial response (PR); twelve patients with stable disease (SD) accounting for 77% with non-progressive disease; five patients showed PD. A 30% decrease of the mean average standardized uptake value (SUV) of sequential PET examinations could be demonstrated; no patient demonstrated a substantial increase in SUV. Patients with PR/SD were matched to a group of nonprogressive disease and tested versus PD. The initial average SUV and SUVmax seem to be candidates for a response prediction with an approximate P-value of 0.06553 and 0.07785, respectively. This is the first larger series of desmoid patients monitored using PET showing that early SUV changes may help to discriminate responders from nonresponders and, thus, to decide whether imatinib therapy should be continued.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2013/389672</identifier><identifier>PMID: 23762842</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Adult ; Age ; Aged ; Benzamides - therapeutic use ; Biomarkers ; Biopsy ; Care and treatment ; Female ; Fibromas ; Fibromatosis, Aggressive - diagnostic imaging ; Fibromatosis, Aggressive - drug therapy ; Fluorodeoxyglucose F18 ; Humans ; Imatinib Mesylate ; Male ; Medical imaging ; Medical research ; Medical treatment ; Middle Aged ; Mutation ; PET imaging ; Piperazines - therapeutic use ; Positron-Emission Tomography ; Pyrimidines - therapeutic use ; Radiation therapy ; Studies ; Treatment Outcome ; Tumors ; Young Adult</subject><ispartof>BioMed research international, 2013-01, Vol.2013 (2013), p.1-7</ispartof><rights>Copyright © 2013 Bernd Kasper et al.</rights><rights>COPYRIGHT 2013 John Wiley & Sons, Inc.</rights><rights>Copyright © 2013 Bernd Kasper et al. Bernd Kasper et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Bernd Kasper et al. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-e7cad89d9727cbe13fb4867542e8d676a5850d3babd6e6114bb93b5bbd335c7c3</citedby><cites>FETCH-LOGICAL-c528t-e7cad89d9727cbe13fb4867542e8d676a5850d3babd6e6114bb93b5bbd335c7c3</cites><orcidid>0000-0001-8425-8356 ; 0000-0002-4909-8999</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671300/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671300/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23762842$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Nikolic, Aleksandra</contributor><creatorcontrib>Sachpekidis, Christos</creatorcontrib><creatorcontrib>Strauss, Ludwig G.</creatorcontrib><creatorcontrib>Pilz, Lothar R.</creatorcontrib><creatorcontrib>Dimitrakopoulou-Strauss, Antonia</creatorcontrib><creatorcontrib>Kasper, Bernd</creatorcontrib><creatorcontrib>Hohenberger, Peter</creatorcontrib><title>Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>We used 2-deoxy-2-[18F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate patients with desmoid tumors undergoing therapy with imatinib. The study included 22 patients with progressive disease (PD) of a biopsy proven desmoid tumor treated orally with imatinib 800 mg daily. Patients were examined using PET prior to onset of therapy and during treatment. Restaging was performed in parallel using computed tomography (CT) and/or magnetic resonance imaging (MRI). Outcome of 22 evaluable patients was as follows: five patients with partial response (PR); twelve patients with stable disease (SD) accounting for 77% with non-progressive disease; five patients showed PD. A 30% decrease of the mean average standardized uptake value (SUV) of sequential PET examinations could be demonstrated; no patient demonstrated a substantial increase in SUV. Patients with PR/SD were matched to a group of nonprogressive disease and tested versus PD. The initial average SUV and SUVmax seem to be candidates for a response prediction with an approximate P-value of 0.06553 and 0.07785, respectively. This is the first larger series of desmoid patients monitored using PET showing that early SUV changes may help to discriminate responders from nonresponders and, thus, to decide whether imatinib therapy should be continued.</description><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Benzamides - therapeutic use</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Care and treatment</subject><subject>Female</subject><subject>Fibromas</subject><subject>Fibromatosis, Aggressive - diagnostic imaging</subject><subject>Fibromatosis, Aggressive - drug therapy</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medical research</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>PET imaging</subject><subject>Piperazines - therapeutic use</subject><subject>Positron-Emission Tomography</subject><subject>Pyrimidines - therapeutic use</subject><subject>Radiation therapy</subject><subject>Studies</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNks1u1DAUhSMEolXpij2yxAaBhvovtrNBqsoAlYqoIKwtO7mZcUnsqZ20mufghfGQMhQ24I2vfD8fXx-donhK8GtCyvKEYsJOmKqEpA-KQ8oIXwjCycN9zdhBcZzSFc5LEYEr8bg4oEwKqjg9LL5fhuTGGDxaDi4ll4s6DGEVzWa9RSYhg75MMYaVGQF9NPEbRNSFiJY3pp_MuONDh-oIZhzAj-gzpE3wCZDz6DL381lCt25co7eQhuBaVE9DiAlNvs1S9RryS9uZOB_yBe_sk-JRZ_oEx3f7UfH13bI--7C4-PT-_Oz0YtGUVI0LkI1pVdVWksrGAmGd5UrIklNQrZDClKrELbPGtgIEIdzaitnS2paxspENOyrezLqbyQ7QNnnWaHq9iW4wcauDcfrPjndrvQo3mglJGMZZ4MWdQAzXE6RRZw8b6HvjIUxJE84VpbSU5b_RrKmkpFxl9Plf6FWYos9OZEGqMJayqn5TK9ODdr4LecRmJ6pPmWQsm_Jzwlcz1cSQUoRu_zuC9S5AehcgPQco08_uG7Jnf8UlAy9nYO18a27d_6lBRqAz92CGeSXYD-j22G4</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Sachpekidis, Christos</creator><creator>Strauss, Ludwig G.</creator><creator>Pilz, Lothar R.</creator><creator>Dimitrakopoulou-Strauss, Antonia</creator><creator>Kasper, Bernd</creator><creator>Hohenberger, Peter</creator><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8425-8356</orcidid><orcidid>https://orcid.org/0000-0002-4909-8999</orcidid></search><sort><creationdate>20130101</creationdate><title>Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib</title><author>Sachpekidis, Christos ; Strauss, Ludwig G. ; Pilz, Lothar R. ; Dimitrakopoulou-Strauss, Antonia ; Kasper, Bernd ; Hohenberger, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-e7cad89d9727cbe13fb4867542e8d676a5850d3babd6e6114bb93b5bbd335c7c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Benzamides - therapeutic use</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Care and treatment</topic><topic>Female</topic><topic>Fibromas</topic><topic>Fibromatosis, Aggressive - diagnostic imaging</topic><topic>Fibromatosis, Aggressive - drug therapy</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medical research</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>PET imaging</topic><topic>Piperazines - therapeutic use</topic><topic>Positron-Emission Tomography</topic><topic>Pyrimidines - therapeutic use</topic><topic>Radiation therapy</topic><topic>Studies</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sachpekidis, Christos</creatorcontrib><creatorcontrib>Strauss, Ludwig G.</creatorcontrib><creatorcontrib>Pilz, Lothar R.</creatorcontrib><creatorcontrib>Dimitrakopoulou-Strauss, Antonia</creatorcontrib><creatorcontrib>Kasper, Bernd</creatorcontrib><creatorcontrib>Hohenberger, Peter</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sachpekidis, Christos</au><au>Strauss, Ludwig G.</au><au>Pilz, Lothar R.</au><au>Dimitrakopoulou-Strauss, Antonia</au><au>Kasper, Bernd</au><au>Hohenberger, Peter</au><au>Nikolic, Aleksandra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>2013</volume><issue>2013</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>We used 2-deoxy-2-[18F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate patients with desmoid tumors undergoing therapy with imatinib. The study included 22 patients with progressive disease (PD) of a biopsy proven desmoid tumor treated orally with imatinib 800 mg daily. Patients were examined using PET prior to onset of therapy and during treatment. Restaging was performed in parallel using computed tomography (CT) and/or magnetic resonance imaging (MRI). Outcome of 22 evaluable patients was as follows: five patients with partial response (PR); twelve patients with stable disease (SD) accounting for 77% with non-progressive disease; five patients showed PD. A 30% decrease of the mean average standardized uptake value (SUV) of sequential PET examinations could be demonstrated; no patient demonstrated a substantial increase in SUV. Patients with PR/SD were matched to a group of nonprogressive disease and tested versus PD. The initial average SUV and SUVmax seem to be candidates for a response prediction with an approximate P-value of 0.06553 and 0.07785, respectively. This is the first larger series of desmoid patients monitored using PET showing that early SUV changes may help to discriminate responders from nonresponders and, thus, to decide whether imatinib therapy should be continued.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>23762842</pmid><doi>10.1155/2013/389672</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-8425-8356</orcidid><orcidid>https://orcid.org/0000-0002-4909-8999</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2013-01, Vol.2013 (2013), p.1-7 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3671300 |
| source | MEDLINE; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Adult Age Aged Benzamides - therapeutic use Biomarkers Biopsy Care and treatment Female Fibromas Fibromatosis, Aggressive - diagnostic imaging Fibromatosis, Aggressive - drug therapy Fluorodeoxyglucose F18 Humans Imatinib Mesylate Male Medical imaging Medical research Medical treatment Middle Aged Mutation PET imaging Piperazines - therapeutic use Positron-Emission Tomography Pyrimidines - therapeutic use Radiation therapy Studies Treatment Outcome Tumors Young Adult |
| title | Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T09%3A21%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Positron%20Emission%20Tomography%20as%20a%20Surrogate%20Marker%20for%20Evaluation%20of%20Treatment%20Response%20in%20Patients%20with%20Desmoid%20Tumors%20under%20Therapy%20with%20Imatinib&rft.jtitle=BioMed%20research%20international&rft.au=Sachpekidis,%20Christos&rft.date=2013-01-01&rft.volume=2013&rft.issue=2013&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2013/389672&rft_dat=%3Cgale_pubme%3EA373372700%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1428007799&rft_id=info:pmid/23762842&rft_galeid=A373372700&rfr_iscdi=true |